A novel biweekly schedule with @entity900 and @entity136 in advanced XXXX .

@entity1 @entity137 @entity390 @entity882 @entity2910 @entity1149 @entity900 @entity1395 @entity391 @entity1398 @entity136
A new schedule with @entity900 and @entity136 administered biweekly was prospectively evaluated in stage IIIB or IV @entity1149 . We report the interim analysis of the safety and efficacy with the first 23 @entity1 included. The mean age was 60. Thirteen @entity1 (56.5%) were stage IIIB and 10 (43.5%) were stage IV The overall response rate was 47.8%: 69.2% for stage IIIB and 20% for stage IV The median survival among the 23 @entity1 was 33 weeks and 1-year survival was 39%: 53.8% for stage IIIB and 20% for stage IV Seventy-seven cycles (154 administrations) were given. The mean number of cycles/ @entity1 was 3.3 (range: 1 to 6). Of the 154 administrations, 26 were delayed 1 week for recovery from @entity137 . The dose intensity (Hryniuk criteria) was 94% of the planned dose. There was one toxic death with grade 4 @entity882 and grade 4 @entity2910 . In two @entity1 , grade 3-4 vascular @entity137 was observed, with distal arterial ischemic changes in the lower extremities. There were three (3.9%) episodes of grade 2 @entity1398 , one (1.7%) of grade 3 and another one of grade 4. No cases of @entity1398 were seen. Predominant nonhematologic @entity137 were @entity1395 and @entity390 / @entity391 . This schedule of @entity900 and @entity136 has a good therapeutic index and, as it is active, enrollment is ongoing to complete the second part of the study.
